

Press release from Emotra AB (publ)

Göteborg, May 31, 2017

## EMOTRA AB: Publication of memorandum

**June 7, 2017, is the first day in the subscription period for the new rights issue in Emotra AB ("Emotra"). This new share issue is also open to the general public. In view of this, we are hereby publishing the Company's memorandum, which can be found on the web sites of Emotra ([www.emotra.se](http://www.emotra.se)), Sedermera Fondkommission ([www.sedermera.se](http://www.sedermera.se)) and AktieTorget ([www.aktietorget.se](http://www.aktietorget.se)). A teaser and subscription form will be published at the beginning of the subscription period.**

The subscription period ends on June 21, 2017. If fully subscribed, this new rights issue will provide Emotra with a cash injection of appr. 17.5 MSEK before issue expenses. The Company has already received subscription commitments for approximately 3 MSEK, or about 17 percent of the issue amount. The object of this rights issue is to strengthen the Company's working capital in anticipation of the market launch of its EDOR® method.

### Investor meetings

In connection with our new rights issue, representatives of Emotra will take part in investor meetings to present the company's operations and future plans. Attending these sessions are free of charge, and we will be serving a light snack. For further information about our meetings, please visit Sedermera Fondkommission's web site ([www.sedermera.se](http://www.sedermera.se)) or contact Sedermera Fondkommission by telephone, +46 40 615 14 10, or by e-mail addressed to [event@sedermera.se](mailto:event@sedermera.se).

Date and time	Organiser	Address and town	Registration
June 9, 2017 11:30 am – 1 pm	Sedermera Fondkommission	Elite Park Avenue Hotel Kungsporsavenyen 36, Göteborg	<a href="mailto:event@sedermera.se">event@sedermera.se</a>
June 14, 2017 11:30 pm – 1 pm	Sedermera Fondkommission	Scandic Klara Slöjdgatan 7, Stockholm	<a href="mailto:event@sedermera.se">event@sedermera.se</a>
June 15, 2017 5:30 pm – 7 pm	Sedermera Fondkommission	Sedermera Fondkommission Norra Vallgatan 64, Malmö	<a href="mailto:event@sedermera.se">event@sedermera.se</a>

### Financial Advisor

Emotra's Financial Advisor in connection with this new rights issue is Sedermera Fondkommission.

### For further information about the rights issue, please contact:

Sedermera Fondkommission  
Telephone: +46 40 615 14 10  
E-mail: [info@sedermera.se](mailto:info@sedermera.se)

### For further information about Emotra, please contact:

Claes Holmberg, CEO  
Telephone: +46 708 25 45 47  
E-mail: [claes@emotra.se](mailto:claes@emotra.se)

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.